SSc can be associated with a high morbidity and mortality. Due to the complexity and heterogeneity of the disease, a composite response measure that will capture differing organ involvements and patient-reported outcomes is desirable. Recently, with participation of the Scleroderma Clinical Trial Consortium, a standardized core set of items were proposed for SSc clinical trials using a structured Delphi exercise. The Delphi exercise identified 11 domains relevant to SSc clinical trials. Currently, efforts are under way to develop a combined response index for clinical trials in diffuse cutaneous SSc.
Introduction
Systemic sclerosis (scleroderma, SSc) is one of the most lethal rheumatic diseases, and is associated with substantial morbidity [1] and many detrimental effects on health-related quality of life. Recent years have seen much progress in the development and validation of outcome measures for SSc [2] . This is paralleled by an increased understanding of the pathogenesis of SSc [3] and development of targeted therapies. Modified Rodnan Skin Score, a measure of skin thickness, has been used as the primary outcome measure in clinical trials of dcSSc. However, due to the complexity and heterogeneity of the disease, a composite response measure that will capture differing organ involvements and patientreported outcomes is desirable. Well-validated, widely accepted combined response indices are more likely to be responsive to change than individual measures [4] , facilitate drug development and improve assessment of efficacy of therapeutic agents [4, 5] .
Recently, with participation of the Scleroderma Clinical Trial Consortium membership, a structured Delphi exercise was conducted to develop a provisional core set of items for clinical trials in SSc [6] . The Delphi exercise selected 31 items from the 11 domains (skin, musculoskeletal, cardiac, pulmonary, gastrointestinal, renal, Raynaud's phenomenon, digital ulcers, health-related quality of life and function, global health and biomarkers) relevant to SSc 1-yr multicentre clinical trials (Table 1 ). All items chosen in the provisional core set are considered to be feasible, reliable and valid in a 1-yr multicentre study. Of the 31 core set items, four were selected that were particularly suited for organ-specific trials: right heart catheterization, 6-min walk test and Borg dyspnoea index were selected for clinical trials where a drug is being assessed specifically for pulmonary hypertension; high-resolution computer tomography was encouraged for trials focusing on lung parenchymal disease. The core set measures are the first step in development of a fully validated composite response index. Although the Delphi methodology has been used successfully to select core set outcome measures in other rheumatic diseases [7] , the principal limitation is that the Delphi methodology is a consensus building approach rather than a datadriven approach.
Researchers at four scleroderma centers in the US are currently performing a prospective longitudinal observational clinical study to gather information on the measurement characteristics of the 31 items in the preliminary core set. These data will be used to further develop a reliable, valid and responsive set of SSc measures and also to develop a validated response index. This is being accomplished through prospective, data-driven, consensus building techniques to develop and quantitatively evaluate candidate definitions for a combined response index for dcSSc as has been done in other rheumatic diseases.
Advantages of standardized core set
Routine use of the core set in patients with dcSSc will greatly facilitate the interpretation of results from clinical trials. Rather than using numerous outcomes that vary from trial to trial, a core set of outcomes will lessen the ambiguity associated with the presentation of multiple test statistics, some of which may be significant and others not. As in SLE, development of a single validated combined response index for clinical trials in dcSSc is a formidable task. Because the 11 domains in the core set are not uniformly involved in all patients, any one or two may dominate the clinical presentation and prognosis. In addition, some potential therapies may be focused on a single domain, while others may attempt to treat the underlying disease process as expressed in multiple domains.
Nevertheless, a combined response index in dcSSc would provide a measure that may improve the ability to measure efficacy and would also facilitate the ability to compare responses across trials. It will likely also allow a decrease in the number of patients necessary for appropriately powered clinical trials, as has been true for the use of combined indices in RA. Regulatory and funding agencies will then have greater confidence in proposals for interventions, and medical professionals and patients will obtain new evidence on the efficacy of various interventions in the short and long term. This will significantly improve the potential to manage dcSSc. Moreover, the combined response index will facilitate the standardization, conduct, reporting and interpretation of clinical trials, may help practitioners to decide if a response has occurred in practice and can also aid in comparing therapies from different trials. The long-term goals are to increase the efficiency of dcSSc clinical trials and facilitate future metaanalyses and comparison of therapies. 
Rheumatology key messages
SSc is a multifaceted disease with substantial morbidity and mortality. Provisional core set items have been proposed for clinical trials in SSc. The scleroderma core set will facilitate the standardization, conduct, reporting and interpretation of clinical trials, and enable the development of a combined response index. 
